Is Wegovy Covered by Insurance?

Why Wegovy Coverage Is Complicated

Insurance coverage for anti-obesity medications has historically lagged behind coverage for other chronic diseases. Obesity affects over 42% of U.S. Adults according to the CDC's National Health and Nutrition Examination Survey, yet payers have been slow to treat it as a reimbursable medical condition. Wegovy sits at the intersection of two coverage categories: weight management and cardiovascular prevention. That dual identity creates both opportunities and confusion.

The FDA Label Expansion Changed the Game

When the FDA approved Wegovy in June 2021, it carried a single indication for chronic weight management in adults with obesity or overweight with at least one comorbidity [1]. The March 2024 label expansion added a cardiovascular risk reduction indication based on the SELECT trial [2]. This second indication opened the door to Medicare Part D coverage, which had previously excluded anti-obesity medications under a statutory exclusion dating back to 2003.

Two Indications, Two Coverage Pathways

Prescribers can now write Wegovy for weight management, cardiovascular risk reduction, or both. The indication on the prescription matters. A cardiologist prescribing Wegovy for a patient with established atherosclerotic cardiovascular disease (ASCVD) may face a different prior authorization pathway than an internist prescribing it for BMI-based obesity alone. Some insurers have created separate formulary tiers for each indication.

Commercial Insurance Coverage

Most large commercial insurers now include Wegovy on their formularies, though placement varies from preferred brand to specialty tier. A 2024 analysis by the Obesity Action Coalition found that approximately 58% of employer-sponsored plans provided some coverage for at least one GLP-1 receptor agonist approved for weight management [3].

Which Plans Cover Wegovy?

UnitedHealthcare, Anthem/Elevance, Aetna, Cigna, and Blue Cross Blue Shield affiliates have all added Wegovy to select formularies. Coverage is plan-specific, not carrier-wide. A BCBS plan in Texas may cover Wegovy while a BCBS plan in Georgia does not. Self-insured employers (who cover roughly 65% of workers with employer-sponsored insurance) make their own formulary decisions, which means two employees at different companies with the same insurer can have completely different coverage.

Typical Prior Authorization Requirements

Nearly every commercial plan requires prior authorization. Common criteria include:

• BMI of 30 kg/m² or higher, or BMI of 27 kg/m² or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• Documentation of failed lifestyle modification (diet, exercise, behavioral counseling) for 3 to 6 months
• Prescription by or in consultation with an endocrinologist, obesity medicine specialist, or primary care physician
• No concurrent use of another GLP-1 receptor agonist
• Step therapy through lower-cost alternatives (some plans require a trial of oral semaglutide or phentermine first)

The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend pharmacotherapy as a first-line adjunct to lifestyle modification for patients with a BMI of 30 or higher, arguing that step therapy through less effective agents delays appropriate treatment [4].

What You Will Pay Out of Pocket

With commercial coverage, expect one of three scenarios. Preferred-tier placement with a copay card can bring costs to $0 to $25 per month. Non-preferred or specialty tier placement typically means $150 to $500 per month after deductible. High-deductible health plans may require full list price until the deductible is met, which can mean $1,349 per month for the first several fills of the year.

Medicare Coverage

The Treat and Reduce Obesity Act and subsequent legislative actions have reshaped Medicare's relationship with anti-obesity medications. The statutory exclusion under Medicare Part D (Section 1862 of the Social Security Act) historically barred coverage of drugs used for "anorexia, weight loss, or weight gain" [5].

The SELECT Trial Changed Medicare Policy

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), published in The New England Journal of Medicine in November 2023, enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher. Semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) compared with placebo over a mean follow-up of 39.8 months [2].

This result gave CMS a pathway to cover Wegovy under Part D when prescribed specifically for cardiovascular risk reduction in patients with established ASCVD. The Centers for Medicare & Medicaid Services issued guidance confirming that the cardiovascular indication falls outside the anti-obesity drug exclusion [6].

Who Qualifies Under Medicare

Medicare Part D covers Wegovy when the prescriber documents established atherosclerotic cardiovascular disease (prior MI, stroke, or symptomatic peripheral artery disease) and a BMI of 27 kg/m² or higher. The prescription must specify the cardiovascular indication. Coverage does not extend to patients seeking Wegovy solely for weight management without documented ASCVD.

Medicare Advantage plans may offer broader coverage. Some MA-PD plans have added Wegovy to supplemental formularies for weight management independent of cardiovascular indication. Check your specific MA plan's formulary, as this varies by region and plan year.

Medicaid Coverage

State Medicaid programs set their own formulary policies for anti-obesity medications. A 2024 report from the Obesity Medicine Association found that fewer than 20 state Medicaid programs covered any FDA-approved anti-obesity medication, and among those, many imposed strict quantity limits or required specialist prescribing [7].

States With and Without Coverage

States like New York, California, and Massachusetts have included GLP-1 agonists for obesity on their Medicaid preferred drug lists. States like Texas and Florida have been slower to add coverage, citing budget impact analyses projecting billions in additional annual spending if utilization reached even 10% of eligible beneficiaries.

The Budget Impact Dilemma

Medicaid programs face a structural challenge. The Medicaid Drug Rebate Program requires coverage of all FDA-approved drugs from manufacturers that participate in the rebate program. Some legal analysts argue this obligates states to cover Wegovy [8]. States have countered by imposing prior authorization criteria strict enough to limit utilization without formally excluding the drug. The result is a patchwork: a Medicaid beneficiary in one state receives coverage while an equally eligible patient across the state line does not.

The Novo Nordisk Savings Program

Novo Nordisk operates a patient savings program for commercially insured patients. Eligible patients with commercial insurance may pay as little as $0 per 28-day supply for up to 13 fills. The program does not apply to patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs [9].

How to Enroll

Patients can register through the Novo Nordisk savings offer website or receive enrollment assistance from their prescriber's office. The savings card is applied at the pharmacy point of sale. Eligibility requires active commercial insurance with some existing Wegovy coverage; the card reduces the patient's cost share, it does not replace insurance coverage entirely.

Limitations

The 13-fill cap means savings expire after approximately one year. After that, the full insurance cost share applies. Patients on high-deductible plans should be aware that manufacturer copay cards do not always count toward deductible accumulation, depending on the plan's accumulator adjustment program policy.

Alternatives When Insurance Denies Coverage

An insurance denial does not end the conversation. Several options remain.

Appeal the Denial

Peer-to-peer review between the prescribing physician and the insurer's medical director overturns denials in a meaningful percentage of cases. The Endocrine Society recommends that providers appeal with documentation of BMI history, comorbidities, prior treatment failures, and relevant clinical trial data supporting the specific patient's profile [10]. A letter of medical necessity citing the SELECT trial results or the STEP trial program data strengthens appeals.

Request an Exception or Tier Reduction

Most plans have a formulary exception process. If Wegovy is on a high cost-sharing tier, the prescriber can request a tier exception, which lowers the copay to a more affordable level. If Wegovy is excluded from the formulary entirely, a coverage exception request may succeed if the prescriber demonstrates that formulary alternatives are medically inappropriate for that patient.

Consider Compounded Semaglutide

During the FDA-declared semaglutide shortage (which began in 2022 and was resolved for certain dosage forms by early 2025), 503B outsourcing facilities produced compounded semaglutide at significantly lower costs. The regulatory status of compounded semaglutide has shifted as shortage declarations are updated. Patients considering this route should verify current FDA shortage status and ensure their compounding pharmacy holds 503B registration [11].

Patient Assistance Programs

Novo Nordisk's patient assistance program (PAP) provides Wegovy at no cost to patients who are uninsured, have no prescription drug coverage, and meet household income criteria (typically at or below 400% of the federal poverty level). Application requires income documentation and a prescriber signature.

What the Clinical Evidence Shows About Cost-Effectiveness

The cost-effectiveness debate directly affects coverage decisions. A 2024 analysis by the Institute for Clinical and Economic Review (ICER) evaluated semaglutide 2.4 mg for obesity and concluded that at a net price of approximately $7,500 to $9,500 per year, Wegovy meets commonly cited willingness-to-pay thresholds of $100,000 to $150,000 per quality-adjusted life year (QALY) [12].

STEP Trial Efficacy Data

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks compared with 2.4% for placebo [13]. The STEP-3 trial (N=611) combined semaglutide with intensive behavioral therapy and reported 16.0% weight loss versus 5.7% for placebo [14]. These effect sizes exceed those of prior anti-obesity medications by a wide margin. Phentermine/topiramate extended-release, the next most effective approved agent, produces approximately 9 to 10% weight loss in clinical trials.

Long-Term Data and the Regain Question

The STEP-1 extension study showed that participants who discontinued semaglutide regained approximately two-thirds of lost weight within one year [15]. This finding has become a central argument in coverage debates. Critics say it proves the drug requires indefinite use and therefore indefinite cost. Proponents, including the Obesity Medicine Association, counter that this pattern mirrors every other chronic disease: stopping antihypertensives causes blood pressure to rise, and stopping statins causes cholesterol to rebound. Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "We would never tell a patient with hypertension to stop their medication because they achieved a normal blood pressure. Obesity deserves the same standard of care."

The American Medical Association recognized obesity as a chronic disease in 2013 [16]. Yet insurance coverage still treats it more like an elective condition than a medical one.

How to Check Your Specific Coverage

Start with these steps before your first appointment.

Call Your Insurer

Contact the number on the back of your insurance card and ask: "Is semaglutide 2.4 mg (Wegovy) on my formulary for the obesity indication? What tier is it on? What prior authorization criteria apply?" Write down the reference number for the call.

Ask Your Prescriber's Office

Many obesity medicine clinics and endocrinology practices have staff dedicated to prior authorization and benefits verification. They can run an electronic benefits check through pharmacy systems before the first prescription is sent.

Check Formulary Databases

Your insurer's online member portal typically includes a formulary search tool. Search by both brand name (Wegovy) and generic name (semaglutide). Some plans list the drug under its cardiovascular indication separately from its obesity indication.

Review Your Summary of Benefits

The Summary of Benefits and Coverage (SBC) document, required by the ACA for all marketplace and employer plans, includes a section on prescription drug coverage. Look for exclusions related to "weight loss drugs" or "anti-obesity medications." If no exclusion is listed, coverage may exist even if the plan has not specifically promoted it.